S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
NASDAQ:IRWD

Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

$11.40
-0.14 (-1.21%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.31
$11.70
50-Day Range
$11.18
$12.56
52-Week Range
$9.73
$12.95
Volume
2.28 million shs
Average Volume
2.03 million shs
Market Capitalization
$1.75 billion
P/E Ratio
12.00
Dividend Yield
N/A
Price Target
$14.67

Ironwood Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
28.7% Upside
$14.67 Price Target
Short Interest
Bearish
10.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
-0.18mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.34 M Sold Last Quarter
Proj. Earnings Growth
4.04%
From $0.99 to $1.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

372nd out of 1,029 stocks

Pharmaceutical Preparations Industry

177th out of 501 stocks

IRWD stock logo

About Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Ironwood Cuts Annual Outlook Below View; Stock Down In Pre-market
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
Ironwood Pharmaceuticals (NASDAQ: IRWD)
2 Health Care Stocks That Fit Graham's Lost Formula
Ironwood Pharmaceuticals Inc
IRWD Ironwood Pharmaceuticals, Inc.
See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Company Calendar

Last Earnings
11/04/2021
Today
2/03/2023
Next Earnings (Confirmed)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+28.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$528.45 million
Pretax Margin
53.84%

Debt

Sales & Book Value

Annual Sales
$413.75 million
Cash Flow
$1.19 per share
Book Value
$3.74 per share

Miscellaneous

Free Float
133,300,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
0.94

Key Executives

  • Thomas A. McCourtThomas A. McCourt
    President, Chief Executive Officer & Director
  • Jason RickardJason Rickard
    Chief Operating Officer & Senior Vice President
  • Sravan Kumar Emany
    Chief Financial Officer & Senior Vice President
  • Marcel Moulaison
    Vice President-Technical Operations
  • Michael ShetzlineMichael Shetzline
    Chief Medical Officer & Senior Vice President













IRWD Stock - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings
or view top-rated stocks.

What is Ironwood Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12-month target prices for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2023?

Ironwood Pharmaceuticals' stock was trading at $12.39 at the beginning of the year. Since then, IRWD stock has decreased by 8.0% and is now trading at $11.40.
View the best growth stocks for 2023 here
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The biotechnology company earned $103.75 million during the quarter, compared to analysts' expectations of $105.27 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 30.24% and a net margin of 39.85%. The business's revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.23 EPS.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $411.00 million-$411.00 million, compared to the consensus revenue estimate of $421.95 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (0.56%), Foundry Partners LLC (0.28%), Monarch Partners Asset Management LLC (0.18%), State of New Jersey Common Pension Fund D (0.13%), Allspring Global Investments Holdings LLC (0.12%) and Assenagon Asset Management S.A. (0.09%). Insiders that own company stock include Alexander J Denner, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.40.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.75 billion and generates $413.75 million in revenue each year. The biotechnology company earns $528.45 million in net income (profit) each year or $0.95 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

The company employs 219 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.

This page (NASDAQ:IRWD) was last updated on 2/4/2023 by MarketBeat.com Staff